


## Biotech-Pharma (Therapy)

### New topical treatment for HPV

A research group from the Andalusian Public Health System (SSPA) has developed a topical treatment for mucocutaneous infections caused by human papillomavirus (HPV)



#### Description

Viral warts are a pathology with an extremely high prevalence among the general population. They are caused by the human papillomavirus (HPV). Most HPV infections are asymptomatic, but when they do produce symptoms they cause the formation of warts (epithelial formations on the skin and mucosa).

It is known that in many cases spontaneous involution of the warts occurs, at a rate of approximately 50% in one year and 93% in five years. However, the involution time is unpredictable and warts can cause discomfort (pain, itching, bleeding, etc.), and they are contagious and unsightly. For this reason, they are usually treated without waiting for any involution to occur.

No specific antivirals are currently available for HPV, and treatment tends to consist in i) the use of abrasive or keratolytic techniques, with a view to destroying the infected tissue, even though the surrounding healthy tissue is also affected, or ii) immunomodulatory techniques to stimulate the immune system to destroy the infected tissue.

Furthermore, there is no scientific evidence as to which the best treatment option is. This highlights the need for new effective therapeutic alternatives to be found that are capable of eliminating mucocutaneous lesions caused by HPV by acting specifically against the virus while affecting only minimally the non-infected surrounding tissue.

The technology developed by the research group from the Andalusian Public Health System is based on a topical treatment for mucocutaneous infections caused by HPV. The compounds selectively inhibit the polymerase of the viral DNA and viral transcriptase. Studies have demonstrated its effectiveness, with high cure rates even in cases of recalcitrant warts, and with no significant side effects.



#### Advantages

1. Antiviral effective when applied topically.
2. Painless and convenient to apply.
3. None or only minimal irritation associated with its use.
4. High rate of efficacy demonstrated.
5. Specific antiviral action as it is an antiviral agent, rather than having a merely "destructive" or immunomodulatory effect, which is what standard methods tend to produce.
6. Low cost treatment compared to other topical antiviral agents or some immunomodulators used.



#### Intellectual Property

This technology is protected by patent.



#### Aims

The research group is looking for a license and/or a collaboration agreement to further develop and exploit the technology.



#### Classification

Area: Biotech-Pharma (Therapy)  
Pathology: Infectious diseases/Dermatology